Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Pancreatic Neoplasms 10Ovarian Neoplasms 10Fallopian Tube Neoplasms 10Lung Neoplasms 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 4Esophageal Neoplasms 4Endometrial Neoplasms 4Oropharyngeal Neoplasms 3Mouth Neoplasms 3Melanoma 3Inflammatory Breast Neoplasms 3Hypopharyngeal Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Pancreatic Adenocarcinoma 2Neoplasms, Squamous Cell 2Neoplasms 2Laryngeal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Brenner Tumor 2Adenocarcinoma of Lung 2

Interventions

pembrolizumab 1Taxes 1Paclitaxel 1Nivolumab 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Adenocarcinoma, Clear Cell × Taxes × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡